CN Patent

CN114796237A — 胆汁淤积性疾病的治疗方法

Assigned to Genfit SA · Expires 2022-07-29 · 4y expired

What this patent protects

本发明涉及胆汁淤积性疾病的治疗方法。具体地，本发明涉及化合物1‑[4‑甲硫基苯基]‑3‑[3,5‑二甲基‑4‑羧基二甲基甲氧基苯基]丙‑2‑烯‑1‑酮(伊拉布诺(Elafibranor)或GFT505)在治疗胆汁淤积性疾病、并更具体是PBC和/或PSC中的应用。

USPTO Abstract

本发明涉及胆汁淤积性疾病的治疗方法。具体地，本发明涉及化合物1‑[4‑甲硫基苯基]‑3‑[3,5‑二甲基‑4‑羧基二甲基甲氧基苯基]丙‑2‑烯‑1‑酮(伊拉布诺(Elafibranor)或GFT505)在治疗胆汁淤积性疾病、并更具体是PBC和/或PSC中的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN114796237A
Jurisdiction
CN
Classification
—
Expires
2022-07-29
Drug substance claim
No
Drug product claim
No
Assignee
Genfit SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.